171 related articles for article (PubMed ID: 37530955)
1. Temporal trends in anticoagulation use and clinical outcomes among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Guo JD; Keshishian A; Delinger R; Russ C; Rosenblatt L; Jiang J; Yuce H; Ferri M
J Thromb Thrombolysis; 2024 Jan; 57(1):1-10. PubMed ID: 37530955
[TBL] [Abstract][Full Text] [Related]
2. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
[TBL] [Abstract][Full Text] [Related]
3. Geographic variation in clinical outcomes and anticoagulation among medicare beneficiaries with non-valvular atrial fibrillation.
Atwater BD; Di Fusco M; Keshishian A; Delinger R; Ferri M; Jiang J; Seigel L; Yuce H; Guo JD
J Thromb Thrombolysis; 2023 Nov; 56(4):626-634. PubMed ID: 37530954
[TBL] [Abstract][Full Text] [Related]
4. Oral anticoagulants usage in Japanese patients aged 18-74 years with non-valvular atrial fibrillation: a retrospective analysis based on insurance claims data.
Ohshima A; Koyama T; Ogawa A; Zamami Y; Tanaka HY; Kitamura Y; Sendo T; Hinotsu S; Miller MW; Kano MR
Fam Pract; 2019 Nov; 36(6):685-692. PubMed ID: 31329899
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
6. Delaying clinical events among patients with non-valvular atrial fibrillation treated with oral anticoagulants: Insights from the ARISTOPHANES study.
Deitelzweig S; Keshishian A; Kang A; Jenkins A; Atreja N; Schuler P; Jiang J; Yuce H; Sun X; Lip GYH
Eur J Intern Med; 2023 Feb; 108():37-42. PubMed ID: 36456387
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.
Dhamane AD; Ferri M; Keshishian A; Russ C; Atreja N; Gutierrez C; Emir B; Yuce H; Di Fusco M
Adv Ther; 2023 Mar; 40(3):887-902. PubMed ID: 36527598
[TBL] [Abstract][Full Text] [Related]
8. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease.
Lopes RD; Steffel J; Di Fusco M; Keshishian A; Luo X; Li X; Masseria C; Hamilton M; Friend K; Gupta K; Mardekian J; Pan X; Baser O; Jones WS
Am J Med; 2018 Sep; 131(9):1075-1085.e4. PubMed ID: 29807001
[TBL] [Abstract][Full Text] [Related]
10. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
Picard F; Ducrocq G; Danchin N; Falissard B; Hanon O; Mahe I; Touzé E; Steg PG
Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
12. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
Falissard B; Picard F; Mahe I; Hanon O; Touzé E; Danchin N; Lamy FX; Ricci L; Steg PG
Arch Cardiovasc Dis; 2019; 112(6-7):400-409. PubMed ID: 31014991
[TBL] [Abstract][Full Text] [Related]
13. The IMPact of untReated nOn-Valvular atrial fibrillation on short-tErm clinical and economic outcomes in the US Medicare population: the IMPROVE-AF model.
Sussman M; Di Fusco M; Tao CY; Guo JD; Gillespie JA; Ferri M; Adair N; Cato MS; Shirkhorshidian I; Barnes GD
J Med Econ; 2021; 24(1):1070-1082. PubMed ID: 34415229
[TBL] [Abstract][Full Text] [Related]
14. Risk of stroke/systemic embolism, major bleeding, and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States medicare population: updated analysis.
Amin A; Keshishian A; Hines DM; Dina O; Le H; Rosenblatt L; Liu X; Zhang Q; Vo L
Curr Med Res Opin; 2022 Dec; 38(12):2131-2140. PubMed ID: 35993487
[TBL] [Abstract][Full Text] [Related]
15. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Rosenblatt L; Liu X; Hede S; Nadkarni A; Shank T
J Manag Care Spec Pharm; 2018 Nov; 24(11):1116-1127. PubMed ID: 30212268
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness and Safety of Direct Oral Anticoagulants Versus Warfarin Among Adults With Cancer and Atrial Fibrillation.
Mehta HB; An H; Ardeshirrouhanifard S; Raji MA; Alexander GC; Segal JB
Circ Cardiovasc Qual Outcomes; 2022 Dec; 15(12):e008951. PubMed ID: 36453260
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of warfarin and dabigatran in patients with non-valvular atrial fibrillation in Japan: A claims database analysis.
Koretsune Y; Yamashita T; Yasaka M; Ono Y; Hirakawa T; Ishida K; Kuroki D; Sumida T; Urushihara H
J Cardiol; 2019 Mar; 73(3):204-209. PubMed ID: 30477926
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Patients With Atrial Fibrillation Newly Recommended for Oral Anticoagulation Under the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society Guideline.
Gray MP; Saba S; Zhang Y; Hernandez I
J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301756
[TBL] [Abstract][Full Text] [Related]
19. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
[TBL] [Abstract][Full Text] [Related]
20. [A comparison of CAS risk model and CHA
Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
[No Abstract] [Full Text] [Related]
[Next] [New Search]